Daiichi Sankyo Company (DSKYF) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The study, titled “Effects of Bempedoic Acid/Ezetimibe/High-intensity Statin on Plaque Regression and Stabilisation of Coronary Atherosclerosis Among Patients Without Cardiovascular Events,” aims to test if a new triple cholesterol treatment can slow or reverse early heart artery disease in high-risk adults. It matters for investors because strong data here could expand use of non-statin drugs in primary prevention.
The trial tests a daily combination of bempedoic acid, ezetimibe, and a high-intensity statin, either rosuvastatin 20 mg or atorvastatin 40 mg. The goal is to cut bad cholesterol and shrink or stabilize plaque in coronary arteries before patients suffer a major event.
This is an interventional Phase 3 study with a single treatment group and no randomization or placebo arm. There is no blinding, so all parties know the treatment, and the main purpose is to see how well this approach treats early coronary artery disease in real-world type patients.
The study was first submitted on 11 March 2026, marking the formal launch of the clinical plan. The last update on 16 March 2026 confirms the trial is not yet recruiting but progressing through setup, which is often when sites and logistics are finalized.
Because this is an early, non-recruiting Phase 3 trial, near-term impact on Daiichi Sankyo’s stock is likely modest, but it adds to the company’s long-term cardiovascular pipeline story. Investors may see this as a signal that DSKYF is pushing beyond traditional statins, in a field where players like Amgen, Novartis, and Esperion are also chasing share.
Over time, positive data could support broader use of triple therapy in patients who have not yet had heart attacks or strokes, expanding the total market for lipid-lowering drugs. That could strengthen pricing power across advanced cholesterol treatments, while disappointing results would mostly trim expectations rather than disrupt the core statin market.
The study is currently in preparation and remains active in setup, with further details and updates available on the ClinicalTrials portal.
To learn more about DSKYF’s potential, visit the Daiichi Sankyo Company drug pipeline page.